ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PLRX / dividends
TLPH (36) XLO (25) HRTX (34) HYFT (45) ⌘ Pro Terminal →

Pliant Therapeutics Inc. (PLRX) Dividend Safety Gauge & 10-Year DRIP Compounder

$0.84 -2.29% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.83

Pliant Therapeutics Inc. (PLRX) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $53.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PLRX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PLRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Pliant Therapeutics Inc. (NASDAQ: PLRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.84 (-2.29% 1D, market cap $53.2M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PLRX compare to TLPH and XLO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PLRX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TLPH (Talphera Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $53.5M) and XLO (Xilio Therapeutics Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $52.8M). Among the 5-stock peer group, PLRX leads on earnings multiple (N/A) while PLRX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PLRX?
▼

Per PLRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001746473), Pliant Therapeutics Inc. generated $437.8M in revenue (-31.5% YoY), $149.3M in net income, and -$128.7M in free cash flow against $225.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.83 (-0.60%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (7)Whales (4)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.7% Base Target
$2 Bull$1 Base$1 Bear
📬 FREE PLRX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PLRX)Realized 20D OHLCV Swing Band: ±12%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY PLRX SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 35.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
42
Grade D$0.99-9.1% Next Q
Q2 (-2Q)
39
Grade E$0.90-5.6% Next Q
Q3 (-1Q)
37
Grade E$0.85-1.2% Next Q
Current
34
Grade E$0.84-8.7% Hist 90D α
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PLRX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PLRX currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.04) and Max Pain ($0.88) forces dealer call-delta covering toward $1.91.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PLRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PLRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr
$10.7K
Yr 1
$11.4K
Yr 2
$12.2K
Yr 3
$13.0K
Yr 4
$13.9K
Yr 5
$14.8K
Yr 6
$15.8K
Yr 7
$16.9K
Yr 8
$18.1K
Yr 9
$19.3K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PLRX)

  • ✓Walkthrough of PLRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PLRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -29.41%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.86H $0.86L $0.84C $0.84VOL 169.5K
RES: $1.19SUP: $0.81SMA50: $1.04SMA200: $1.16
$1.46$1.29$1.12$0.95$0.78RES $1.19SUP $0.81$0.842026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PLRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PLRX Butterfly Map → + Track PLRX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -31.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PLRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PLRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PLRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PLRX)

Health Care Rank #641 of 1015 ⚔️ TLPH vs PLRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PLRX vs. TLPH, XLO, HRTX, HYFT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Pliant Therapeutics Inc. (PLRX) ranks #641 by composite RQD confidence (34/100, grade E) and #735 by equity capitalization ($53.2M). Within this direct 5-issuer industry benchmark cohort, PLRX leads on earnings valuation at N/A trailing P/E, while PLRX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. HYFT currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with PLRX at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PLRX ACTIVE
Pliant Therapeutics Inc.
E 34/100 — — -35.0% -2.29% $53.2M Benchmark Subject
TLPH
Talphera Inc.
D- 36/100 — — -35.0% -1.94% $53.5M /tlph-vs-plrx →
XLO
Xilio Therapeutics Inc.
E 25/100 — — -35.0% -0.50% $52.8M /xlo-vs-plrx →
HRTX
Heron Therapeutics Inc.
E 34/100 — 73.3% -35.0% +6.27% $52.7M /hrtx-vs-plrx →
HYFT
MindWalk Holdings Corp.
D 45/100 — — — -2.65% $53.8M /hyft-vs-plrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001746473 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pliant Therapeutics Inc. (PLRX) reported GAAP revenue of $437.8M (-31.5% vs. FY2024 revenue of $639.4M , and +27611.7% cumulative change since FY2023) , GAAP net income of $149.3M, operating cash flow of -$128.3M, and free cash flow of -$128.7M (+19.2% YoY). On the balance sheet, PLRX closed FY2025 with $225.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $437.8M $149.3M -$128.3M -$128.7M $225.2M —
FY2024 (FY) 2024-12-31 $639.4M $210.3M -$155.5M -$159.4M $396.9M —
FY2023 (FY) 2023-12-31 $1.6M $161.3M -$116.4M -$116.4M — —

3. PLRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PLRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Pliant Therapeutics Inc. (NASDAQ: PLRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.84 (-2.29% 1D, market cap $53.2M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

How does PLRX compare to TLPH and XLO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PLRX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TLPH (Talphera Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $53.5M) and XLO (Xilio Therapeutics Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $52.8M). Among the 5-stock peer group, PLRX leads on earnings multiple (N/A) while PLRX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PLRX?

Per PLRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001746473), Pliant Therapeutics Inc. generated $437.8M in revenue (-31.5% YoY), $149.3M in net income, and -$128.7M in free cash flow against $225.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PLRX trading relative to its 50-day, 200-day, and 52-week technical levels?

PLRX last traded at $0.84 (-2.29% on volume of 385,692 shares), positioning the stock -19.23% below its 50-day simple moving average ($1.04) and -27.59% below its 200-day simple moving average ($1.16). Across its 52-week range of $0.83 to $1.82, PLRX sits at the 1.0% percentile with a 14-day RSI of 35.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.0% ($1.00 to $0.94).

Direct Sub-Reports: PLRX RQD Cockpit PLRX 12M Forecast PLRX Earnings & Move PLRX Dividends & DRIP PLRX Insiders & 13F PLRX Whale Options PLRX Profit Sankey PLRX News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

PLRX — Pliant Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Pliant Therapeutics Inc. (PLRX) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.84 (-2.29% 1D, market capitalization $53.2M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Pliant Therapeutics Inc. (PLRX) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The profile does not describe its products, customers, or revenue model. The financials report revenue of — for FY 2025 and FY 2024 and $1.6M for FY 2023 ().

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Pliant Therapeutics Inc. (PLRX) reported $437.8M in annual revenue (up from $639.4M in FY2024, -31.5% YoY) and $149.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.6M revenue, $161.3M net income) through FY2025, PLRX scaled operating cash flow to -$128.3M and free cash flow to -$128.7M, backed by $225.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 4/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $0.83 – $1.82 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), PLRX carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can PLRX sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $437.8M and free cash flow of -$128.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PLRX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PLRX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Pliant Therapeutics Inc. (PLRX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PLRX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PLRX Bull vs. Bear Conversation Board — What's Your Call at $0.84?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PLRX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PLRX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $1.08 (+25.6%)
📌 Pinned Debate

Institutional accumulation and options positioning earn the stock 12 of 20 on the whale-flow pillar, the strongest of its five scores.

Long PLRX at $0.86 targeting $1.08. Institutional accumulation and options positioning earn the stock 12 of 20 on the whale-flow pillar, the strongest of its five scores.. Institutional whale score is 4/20 and the risk/reward vs. the $0.83 52-week low is skewed heavily in favor of bulls.

CapAlloc_Nerd 🐂 BULL

@FadeTheHype Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $0.66 (-23.3%)
Spot @ $0.86

ROIC of -35% and 0% FCF yield, with free cash outflows of $116M–$159M against $45.4M of cash, point to a cash-consumptive business with

I respect the product at Pliant Therapeutics Inc., but the stock at $0.86 is a different story. ROIC of -35% and 0% FCF yield, with free cash outflows of $116M–$159M against $45.4M of cash, point to a cash-consumptive business with runway and dilution risk.. FCF yield is 0.0% and RQD sits at 34/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%